 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C11H16N5O7PS |
| Molecular Weight | 393.31 |
| Exact Mass | 393.051 |
| CAS # | 22140-20-1 |
| Related CAS # | 2-Methylthio-AMP diTEA;1227193-98-7 |
| PubChem CID | 189762 |
| Appearance | White to off-white solid powder |
| LogP | -2.7 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 25 |
| Complexity | 529 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N |
| InChi Key | XVTFTCNRRAQHEQ-KQYNXXCUSA-N |
| InChi Code | InChI=1S/C11H16N5O7PS/c1-25-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(23-10)2-22-24(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1 |
| Chemical Name | [(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | P2Y12 Receptor |
| ln Vitro | 2-Methylthio-AMP (2-MeSAMP) prevents platelets from activating αIIbβ3 when triggered by an agonist[1]. Thrombin, PAR1-AP, PAR4-AP, and ADP-mediated platelet Ca2+ mobilization are not significantly inhibited by 2-methylthio-AMP (50 μM; for 5 minutes). 2-methylthio-AMP does not increase cAMP or cause vasodilator-stimulated phosphoprotein phosphorylation in wild-type platelets, nor does it block Ca2+ mobilization in P2Y12-deficient mouse platelets[1]. |
| References |
[1]. Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects. J Pharmacol Exp Ther. 2014 Oct;351(1):33-43. [2]. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2434-42. [3]. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (254.25 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5425 mL | 12.7126 mL | 25.4252 mL | |
| 5 mM | 0.5085 mL | 2.5425 mL | 5.0850 mL | |
| 10 mM | 0.2543 mL | 1.2713 mL | 2.5425 mL |